Nachrichten zur Regeneron Pharmaceuticals Inc. Aktie

XFRA : ZERTIFIKATEBOERSE RESUMPTION OF UNDERL.: US75886F1075

ALLE STRUKTURIERTEN PRODUKTE MIT UNDERLYING US75886F1075 SIND AB 28.06.2023 WIEDER IN DEN HANDEL AUFGENOMMEN. ALL STRUCTURED PRODUCTS WITH UNDERLYING US75886F1075 ARE…

XFRA : RGO: Wiederaufnahme/Resumption

FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE. THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING…

XETR : INSTRUMENT_SUSPENSION - US75886F1075

Instrument ID [8601410] (RGO - US75886F1075) suspended...…

Regeneron shares fall after FDA rejects high-dose eye disease treatment

Regeneron said the rejection was "solely due to an ongoing review of inspection findings at a third-party filler."...…

XFRA : RGO: Aussetzung/Suspension

DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT: THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT: INSTRUMENT NAME …

XFRA : ZERTIFIKATEBOERSE SUSPENSION OF UNDERL.: US75886F1075

ALLE STRUKTURIERTEN PRODUKTE MIT UNDERLYING US75886F1075 SIND AB SOFORT VOM HANDEL AUSGESETZT BIS AUF WEITERES. ALL STRUCTURED PRODUCTS WITH UNDERLYING US75886F1075…

Regeneron Stock Slumps After FDA Decision Delays Blockbuster Release

The Food and Drug Administration rejected its application for approval of a new, higher-dose version of eye disease treatment Eylea....…

Regeneron Gets FDA Response Letter on Aflibercept 8 Mg Application, Says Issue Involves Third-Party Filler

Regeneron Gets FDA Response Letter on Aflibercept 8 Mg Application, Says Issue Involves Third-Party Filler...…

Regeneron high-dose Eylea version rejected by FDA

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Regeneron’s high-dose Eylea not approved by FDA

Regeneron Pharmaceuticals Inc. REGN said Tuesday that the U.S. Food and Drug Administration issued a complete response letter for the…

US FDA declines to approve Regeneron high-dose Eylea

...(Reuters) - The U.S. Food and Drug Administration on Tuesday......…

UPDATE 1-US FDA declines to approve Regeneron high-dose Eylea

... in paragraphs 2, 5) June 27 (Reuters) - The U.S. Food and Drug Administration......…

Regeneron shares halted at $773.91 on pending news

Um den gesamten Artikel unter marketwatch.com zu lesen, klicken Sie bitte auf die Überschrift...…

Regeneron (REGN) Outpaces Stock Market Gains: What You Should Know

Regeneron (REGN) closed at $771.11 in the latest trading session, marking a +0.49% move from the prior day....…

Form 8-K REGENERON PHARMACEUTICAL For: Jun 09

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

18 Analysts Have This to Say About Regeneron Pharmaceuticals

Latest Ratings for REGN DateFirmActionFromTo Feb 2022Truist SecuritiesMaintainsBuy Feb 2022OppenheimerMaintainsOutperform Feb 2022Morgan StanleyMaintainsEqual-Weight View More…

Regeneron (REGN) Outpaces Stock Market Gains: What You Should Know

In the latest trading session, Regeneron (REGN) closed at $750.12, marking a +1.56% move from the previous day....…

XETR : MARKET_RESET for Partition ID [56] - RGO Product ID [586419]

Market Reset. Product ID: [586419](US75886F1075) Product State: HALT Last msg key: 16854824046667781511...…

Regeneron (REGN) Posts Upbeat Data From Multiple Myeloma Study

A mid-stage study data shows that treatment with Regenerons (REGN) experimental antibody achieved a 71% objective response rate in heavily…

The Zacks Analyst Blog Highlights AbbVie, Intel, Qualcomm, Regeneron and CME Group

AbbVie, Intel, Qualcomm, Regeneron and CME Group are included in this Analyst Blog....…

Sanofi:Dupixent Phase 3 COPD Results Presented At ATS & Published In New England Journal Of Medicine

PARIS (dpa-AFX) - Sanofi and Regeneron Pharmaceuticals Inc. (REGN) presented positive Phase 3 results evaluating the investigational use of Dupixent…

Regeneron (REGN) Faces Challenges as Eylea Sales Decline

Regeneron (REGN) loses some of its gains as sales of its lead drug, Eylea, decline. Nevertheless, Dupixent sales boost the…

U.S. Supreme Court Rules Against Amgen In Cholesterol Drug Patent Dispute With Sanofi

THOUSAND OAKS (dpa-AFX) - The U.S. Supreme Court ruled against Amgen (AMGN) in a long-running patent battle with Sanofi (SNY)…

Regeneron Announces Investor Conference Presentations

TARRYTOWN, N.Y., May 18, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as…

Regeneron Says Supreme Court Ruling Ends Patent Dispute With Amgen

Regeneron Says Supreme Court Ruling Ends Patent Dispute With Amgen...…

Supreme Court rules against Amgen in Repatha patent dispute with Sanofi/ Regeneron

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Regeneron CEO supports FTC suit against Amgen acquisition of Horizon - FT

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Regeneron (REGN) Q1 Earnings & Sales Top, Eylea Sales Decline

Regeneron (REGN) beats earnings and sales estimates in first-quarter 2023 fueled by Dupixent. However, sales of the lead drug Eylea…

Why Regeneron Pharmaceuticals Stock Is Tanking Today

Investors are worried about Eyleas falling sales....…

Regeneron tops Q1 estimates but lowers margin guidance, sending stock lower

Regeneron Pharmaceuticals Inc. ‘s stock REGN slid 4% premarket Thursday, after the company topped estimates for first-quarter earnings but …

Form 10-Q REGENERON PHARMACEUTICAL For: Mar 31

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Form 8-K REGENERON PHARMACEUTICAL For: May 04

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Regeneron Pharmaceuticals Q1 Profit Decreases, but beats estimates

WASHINGTON (dpa-AFX) - Regeneron Pharmaceuticals (REGN) announced earnings for first quarter that decreased from the same period last year but…

Regeneron beats quarterly profit estimates on Dupixent strength

...(Reuters) -Regeneron Pharmaceuticals Inc beat Wall Street estimates......…

Regeneron Posts Higher 1Q Sales, Boosted by Sanofi Work

Regeneron Posts Higher 1Q Sales, Boosted by Sanofi Work...…

Regeneron beats quarterly profit estimates on Eylea strength

...May 4 (Reuters) - Regeneron Pharmaceuticals Inc beat Wall Street......…

Regeneron Reports First Quarter 2023 Financial and Operating Results

TARRYTOWN, N.Y., May 04, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for…

Regeneron looks to strong Dupixent, Eylea sales in Q1 report

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Why Earnings Season Could Be Great for Regeneron (REGN)

Regeneron (REGN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season....…

Alnylam und Regeneron melden positive klinische Zwischenergebnisse der Phase 1 zu ALN-APP, einem RNAi-Prüftherapeutikum für Alzheimer-Krankheit und zerebrale Amyloidangiopathie

CAMBRIDGE, Massachusetts, und TARRYTOWN, New York--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) und Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) meldeten heute positive…

Insiderhandel: Aufsichtsrat verkauft Aktien von Regeneron Pharmaceuticals im Wert von 2.451.149$

Brown, Michael S. - Aufsichtsrat - Tag der Transaktion: 2023-04-21...…

Regeneron (REGN) Outpaces Stock Market Gains: What You Should Know

In the latest trading session, Regeneron (REGN) closed at $800.73, marking a +0.33% move from the previous day....…

Regeneron Pharmaceuticals Chairman P. Roy Vagelos to Retire

Regeneron Pharmaceuticals Chairman P. Roy Vagelos to Retire...…

Regeneron Announces Retirement of Board Chair, Dr. P. Roy Vagelos, Accomplished Physician-Businessman and Industry Luminary

Dr. Leonard S. Schleifer and Dr. George D. Yancopoulos to become Co-Chairs of the Board and Christine A. Poon to…

dpa-AFX ProFeed